Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 15/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 14/20 | 0.59 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29211974 | 0.97 | CYP3A4 (0.59) | CYP3A4CYP2D6FGFR1ADORA2AADORA1 | |
| SCHEMBL29287913 | 0.93 | CYP3A4 (0.59) | CYP3A4CYP2D6FGFR1ADORA2AADORA1 | |
| SCHEMBL29287935 | 0.93 | CYP3A4 (0.59) | CYP3A4CYP2D6FGFR1ADORA2AADORA1 | |
| SCHEMBL28900522 | 0.88 | CYP3A4 (0.69) | CYP3A4CYP2D6FGFR1 | |
| SCHEMBL28977842 | 0.87 | CYP3A4 (0.60) | CYP3A4CYP2D6FGFR1 | |
| SCHEMBL29287919 | 0.84 | CYP3A4 (0.53) | CYP3A4CYP2D6FGFR1 | |
| SCHEMBL29287933 | 0.84 | CYP3A4 (0.53) | CYP3A4CYP2D6FGFR1 | |
| SCHEMBL29287915 | 0.83 | CYP3A4 (0.53) | CYP3A4CYP2D6FGFR1 | |
| SCHEMBL29211963 | 0.82 | CYP3A4 (0.61) | CYP3A4CYP2D6ADORA2AADORA1 | |
| SCHEMBL29211964 | 0.82 | CYP3A4 (0.61) | CYP3A4CYP2D6ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109320553-B | Nucleoside reverse transcriptase inhibitors for antiviral use | 深圳市塔吉瑞生物医药有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-109320553-A | Novel nucleoside reverse transcriptase inhibitors for antiviral use | 深圳市塔吉瑞生物医药有限公司 | 2019-02-12 | — | — | CN | disclosed |